Back to reports
Wish List 0 Cart
0

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Disease – Global Clinical Trials Review, H1 2020

Pages: 183 Published: May 30, 2020 Report Code: GDHC6245CTIDB

Add to Wishlist
Select Item

GlobalData's clinical trial report, “Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Global Clinical Trials Review, H1, 2020" provides an overview of Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Clinical trials scenario. This report provides top line data relating to the clinical trials on Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma – Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

– The report provides a snapshot of the global clinical trials landscape

– Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

– The Report provides enrollment trends for the past five years

– Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to Buy

– Assists in formulating key business strategies with regards to investment

– Helps in identifying prominent locations for conducting clinical trials which saves time and cost

– Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

– Supports understanding of trials count and enrollment trends by country in global therapeutics market

– Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

– Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Key Players

  • UroGen Pharma Ltd

    Merck & Co Inc

    Spectrum Pharmaceuticals Inc

    Anchiano Therapeutics Ltd

    Asieris Pharmaceuticals Co Ltd

    AstraZeneca Plc

    Bristol-Myers Squibb Co

    Liminal BioSciences Inc

    CG Oncology Inc

    Altor Bioscience LLC

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Report Guidance 7

GlobalData Clinical Trials Report Coverage 8

Clinical Trials by Region 9

Clinical Trials and Average Enrollment by Country 10

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 13

Top Five Countries Contributing to Clinical Trials in Europe 14

Top Countries Contributing to Clinical Trials in North America 15

Top Countries Contributing to Clinical Trials in Middle East and Africa 16

Top Countries Contributing to Clinical Trials in Central and South America 17

Clinical Trials by G7 Countries: Proportion of Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) to Oncology Clinical Trials 18

Clinical Trials by Phase in G7 Countries 20

Clinical Trials in G7 Countries by Trial Status 22

Clinical Trials by E7 Countries: Proportion of Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) to Oncology Clinical Trials 24

Clinical Trials by Phase in E7 Countries 26

Clinical Trials in E7 Countries by Trial Status 27

Clinical Trials by Phase 29

In Progress Trials by Phase 30

Clinical Trials by Trial Status 31

Clinical Trials by End Point Status 33

Subjects Recruited Over a Period of Time 34

Clinical Trials by Sponsor Type 35

Prominent Sponsors 36

Top Companies Participating in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials 38

Prominent Drugs 40

Latest Clinical Trials News on Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) 42

Feb 25, 2020: Theralase advances its pivotal phase II non-muscle invasive bladder cancer study with a new clinical study site in Nova Scotia 42

Clinical Trial Profile Snapshots 43

Appendix 181

Abbreviations 181

Definitions 181

Research Methodology 182

Secondary Research 182

About GlobalData 183

Contact Us 183

Disclaimer 183

Source 184

List of Tables

List of Tables

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, Global, Clinical Trials by Region, 2020* 8

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2020* 10

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2020* 11

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2020* 12

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Europe, Top Five Countries, 2020* 13

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, North America, Top Countries, 2020* 14

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2020* 15

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Central and South America, Top Countries, 2020* 16

Proportion of Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) to Oncology Clinical Trials, G7 Countries (%), 2020* 18

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, G7 Countries, Clinical Trials by Phase, 2020* 20

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2020* 22

Proportion of Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) to Oncology Clinical Trials, E7 Countries (%), 2020* 24

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, E7 Countries, Clinical Trials by Phase, 2020* 25

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2020* 27

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, Global, Clinical Trials by Phase, 2020* 28

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, Global, Clinical Trials In Progress by Phase 2020* 29

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, Global, Clinical Trials by Trial Status, 2020* 31

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Global, by End Point Status, 2020* 32

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2015-2019 33

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2020* 34

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Global, Key Sponsors, 2020* 36

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2020* 38

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2020* 40

List of Figures

List of Figures

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, Global, Clinical Trials by Region (%), 2020* 8

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2020* 9

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2020* 11

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2020* 12

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2020* 13

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, North America, Top Countries (%), 2020* 14

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2020* 15

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2020* 16

Proportion of Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) to Oncology Clinical Trials, G7 Countries (%), 2020* 17

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, G7 Countries, Clinical Trials by Phase, 2020* 19

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2020* 21

Proportion of Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) to Oncology Clinical Trials, E7 Countries (%), 2020* 23

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, E7 Countries, Clinical Trials by Phase, 2020* 25

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2020* 26

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, Global, Clinical Trials by Phase (%), 2020* 28

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, Global, Clinical Trials In Progress by Phase, 2020* 29

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics, Global, Clinical Trials by Trial Status, 2020* 30

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Global, by End Point Status, 2020* 32

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2015-2019 33

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2020* 34

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Global, Key Sponsors, 2020* 35

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2020* 37

Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2020* 39

GlobalData Methodology 181

 

Frequently Asked Questions

Buy Now

Add to Basket
Enquire Before Buying
$2500

Can be used by individual purchaser only

Most Popular
$5000

Can be shared by unlimited users within one corporate location e.g. a regional office

$7500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.

Related reports

View more Pharmaceuticals reports
Pharmaceuticals
New
New
Human cytomegalovirus 65 kDa Phosphoprotein (PP65 or 65 kDa Matrix Phosphoprotein or Tegument Protein UL83 or UL83) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
$3500 | August 12, 2022
Pharmaceuticals
New
New
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
$3500 | August 12, 2022
Pharmaceuticals
New
New
Clinical Trials – The Importance of Diversity in Clinical Trials
$695 | August 12, 2022